Sign in

You're signed outSign in or to get full access.

Matthew Caufields

Research Analyst at H.C. Wainwright

Matthew Caufield is an analyst at H.C. Wainwright & Co., specializing in healthcare and biotechnology sector research. He covers specific companies including Aldeyra Therapeutics (ALDX), IVERIC bio (ISEE), RegenXBio (RGNX), Opthea (OPT), HilleVax (HLVX), Optinose (OPTN), Oyster Point Pharma (OYST), Disc Medicine (IRON), and Akebia Therapeutics, with a performance track record showing a 38-46% success rate, average returns ranging from -4.4% to +16.0% per rating, and his best call on ALDX generating +290% return. Caufield has been active issuing ratings since at least 2022, primarily at H.C. Wainwright with no prior firms detailed in available data. His professional credentials include recognition as a Wall Street analyst ranked around #1,060-#9,066 on TipRanks, though specific FINRA licenses are not specified.

Matthew Caufields's questions to ARDELYX (ARDX) leadership

Question · Q4 2025

Matthew Caufields inquired about the greatest distinctions IBSRELA will offer in the future CIC market compared to other mechanisms like GCC agonists or serotonin receptor agonists, focusing on unmet need and differentiation.

Answer

Chief Patient Officer and Interim Chief Medical Officer Laura Williams highlighted the need for different mechanisms of action in CIC, similar to IBS-C, due to patients remaining symptomatic on existing treatments. CEO Mike Raab emphasized the evolving understanding of functional gut disorders and IBSRELA's NHE3 inhibition as a distinct choice compared to secretagogues and motility drugs.

Ask follow-up questions

Fintool

Fintool can predict ARDELYX logo ARDX's earnings beat/miss a week before the call

Question · Q4 2025

Matthew Caufields from H.C. Wainwright & Co. asked about the key distinctions IBSRELA would offer in the future CIC market compared to other GCC agonists or serotonin receptor agonists, and the specific unmet needs and differentiation it addresses.

Answer

Chief Patient Officer and Interim Chief Medical Officer Laura Williams highlighted the fluidity between IBS-C and CIC and the need for different mechanisms of action, as many patients on existing drugs remain symptomatic. CEO Mike Raab emphasized that IBSRELA's NHE3 inhibition offers a distinct choice compared to secretagogues (GCC agonists) and serotonin receptor agonists, which are motility drugs, aligning with the evolving understanding of the continuum between CIC and IBS-C.

Ask follow-up questions

Fintool

Fintool can write a report on ARDELYX logo ARDX's next earnings in your company's style and formatting